2022
Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.Peer-Reviewed Original ResearchImmune-related adverse eventsTriple-negative breast cancerMultivariate logistic regression analysisPD-L1 statusLogistic regression analysisAA raceOverall survivalPathologic responseClinical trialsBreast cancerEarly-stage triple-negative breast cancerIncidence of irAEsPhase I/II trialPathologic complete response rateSignificant associationPhase I/II clinical trialsBaseline body mass indexSafety of immunotherapyWeekly nab-paclitaxelCharlson Comorbidity IndexComplete response ratePrimary efficacy endpointPD-L1 expressionBody mass indexBreast cancer recurrence
2016
Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers
Park TS, Groh EM, Patel K, Kerkar SP, Lee CC, Rosenberg SA. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers. Journal Of Immunotherapy 2016, 39: 1-7. PMID: 26641256, PMCID: PMC6453128, DOI: 10.1097/cji.0000000000000101.Peer-Reviewed Original ResearchConceptsNY-ESO-1Cancer-testis antigensExpression of MAGESquamous cell carcinomaCell carcinomaNY-ESO-1 expressionHigh expressionImmune-based therapiesSquamous cell cancerDurable tumor regressionMetastatic melanoma lesionsTargeted immunotherapyCell cancerMelanoma patientsSynovial sarcomaMetastatic melanomaPrimary tumorTumor regressionClinical trialsCancer histologyMetastatic cancerCTA expressionSame patientTestis antigensPatients